Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;32(8):1053-1055.
doi: 10.1016/j.annonc.2021.04.019. Epub 2021 Apr 28.

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

J Barrière  1 , E Chamorey  2 , Z Adjtoutah  3 , O Castelnau  4 , A Mahamat  4 , S Marco  4 , E Petit  4 , A Leysalle  5 , V Raimondi  3 , M Carles  6
Affiliations

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

J Barrière et al. Ann Oncol. 2021 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1
Humoral quantitative anti-spike (S) antibody (logarithmic scale) response at week (w) 3-w4 and w6-w8 from dose 1 of BNT162b2 (Pfizer/BioNtech) messenger RNA (mRNA) vaccine in patients with active treatment for cancer (G1; n = 122) and in a healthy volunteer (HV) group (G2; n = 24). a-G1W3-4: cohort of patients with active treatment for cancer at w3-w4/from dose 1 of BNT162b2 (Pfizer/BioNtech) mRNA vaccine (date of booster dose); b-G2W3-4: HV group at w3-w4; c-G1W6-8: cohort of patients at w6-w8 from dose 1 of vaccine; d-G2W6-8: HV group at w6-w8.
See this image and copyright information in PMC

Comment in

References

    1. Wang Q., Berger N.A., Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2021;7(2):220–227. - PMC - PubMed
    1. Barrière J., Gal J., Hoch B. Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Ann Oncol. 2021;32(5):673–674. - PMC - PubMed
    1. Boyarsky B.J., Werbel W.A., Avery R.K. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325(17):1784–1786. - PMC - PubMed
    1. Meerveld-Eggink A., de Weerdt O., van der Velden A.M.T. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol. 2011;22(9):2031–2035. - PubMed
    1. Rousseau B., Loulergue P., Mir O. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol. 2012;23(2):450–457. - PubMed